サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1794454

甲状腺髄様がんの世界市場

Medullary Thyroid Cancer

出版日
ページ情報
英文 281 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=149.79円
甲状腺髄様がんの世界市場
出版日: 2025年08月20日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 281 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

甲状腺髄様がんの世界市場は2030年までに22億米ドルに達する

2024年に14億米ドルと推定される甲状腺髄様がんの世界市場は、2024年から2030年にかけてCAGR 7.6%で成長し、2030年には22億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである外科治療は、CAGR 8.9%を記録し、分析期間終了時には14億米ドルに達すると予測されます。放射線治療分野の成長率は、分析期間中CAGR 5.2％と推定されます。

米国市場は推定3億8,330万米ドル、中国はCAGR12.1％で成長予測

米国の甲状腺髄様がん市場は、2024年に3億8,330万米ドルと推定されます。世界第2位の経済大国である中国は、分析期間2024-2030年のCAGRを12.1%として、2030年までに4億6,800万米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ3.7%と7.4%と予測されています。欧州では、ドイツがCAGR 5.0%で成長すると予測されています。

世界の甲状腺髄様がん市場- 主要動向と促進要因のまとめ

甲状腺悪性腫瘍の中で甲状腺髄様がんがユニークなのはなぜか？

甲状腺髄様がん（MTC）は、甲状腺悪性腫瘍の中でも独特で比較的まれな形態として際立っており、全世界の甲状腺がん症例の約3～4％を占めています。濾胞細胞から発生する一般的な甲状腺乳頭がんや濾胞がんとは異なり、MTCはカルシトニンというホルモンを産生する濾胞傍C細胞から発生します。このユニークな起源により、MTCは生物学的挙動、臨床像、治療アプローチが異なります。MTCは散発的に、あるいは多発性内分泌腫瘍2型（MEN2）のような遺伝性症候群の一部として起こりうるため、遺伝子検査は診断およびリスク層別化の要となります。カルシトニン値およびカルサイノエンブリオニック抗原（CEA）値の上昇は、早期発見および疾患モニタリングのための重要なバイオマーカーとなります。分化型甲状腺がんと異なり、MTCは一般的に放射性ヨードを吸収しないため、従来の甲状腺がん治療の有効性が制限されます。甲状腺全摘術とリンパ節郭清を伴うことが多いです。しかし、この病気は早期のリンパ節転移や遠隔転移、特に肝臓や肺への転移を起こしやすいため、長期的な管理が複雑になります。さらに、遺伝性の患者は若年で発症することが多く、他の内分泌腫瘍を発症する可能性もあるため、臨床的な複雑さがさらに増します。これらの要因により、MTCは早期診断、個々の患者に合った治療戦略、生涯にわたるモニタリングの必要性が強調され、臨床的に管理するのが最も困難な甲状腺がんの1つとなっています。

分子生物学と遺伝子検査の進歩は、診断とリスク評価をどのように変えているのでしょうか？

甲状腺髄様がんの理解は、分子生物学と遺伝子検査の進歩によって著しく向上し、診断とリスク評価の両方に不可欠なものとなりました。特にMEN 2AやMEN 2Bのような家族性症候群に関連する症例において、RET原遺伝子の変異が同定されたことは画期的な開発でした。リスクのある人の遺伝子スクリーニングにより、早期発見と予防的甲状腺摘出術が可能となり、これにより生存成績が劇的に改善することが示されています。散発例では、体細胞RET突然変異とRAS突然変異が、腫瘍の挙動と潜在的な治療反応についての洞察を提供します。遺伝子プロファイルに基づいて患者を層別化できるようになったことで、治療アプローチやフォローアッププロトコールがより個別化されるようになりました。分子診断法はまた、従来の画像診断や細胞診で結論が得られない場合に、甲状腺結節の良性・悪性の鑑別を容易にします。リキッドバイオプシー法は、まだ始まったばかりではあるが、病気の進行や再発を非侵襲的にモニターするのに有望です。これらの分子生物学的知見は、カルシトニンやCEAのような血清バイオマーカーによって補完されます。さらに、遺伝カウンセリングは遺伝性MTC患者のケアにおいて重要な要素となっており、家族全体のリスク評価と予防戦略を可能にしています。プレシジョン・メディシンが進化し続ける中、遺伝学的および分子学的データの統合により、診断精度がさらに向上し、この侵攻性の甲状腺がん患者の個別化管理が改善されることが期待されます。

治療状況の変化において、標的治療薬と新薬はどのような役割を果たすのか？

甲状腺髄様がんの治療状況は、標的治療と新薬開発の出現によって一変しました。進行性、手術不能、または転移性のMTC患者にとって、従来の化学療法や放射線療法は有効性に限界があり、より効果的な全身的治療法の探索を促しています。バンデタニブやカボザンチニブなどのチロシンキナーゼ阻害剤（TKI）は、このような症例、特に進行性の患者に対する最前線の治療薬として登場しました。これらの薬剤は、RETおよび腫瘍増殖と血管新生に関与する他の経路を阻害することにより作用し、無増悪生存期間の延長と病勢コントロールをもたらします。さらに最近では、セルペルカチニブやプラルセチニブのような高選択的RET阻害剤が、特にRET変異腫瘍患者において、オフターゲット効果の少ない有意な臨床効果を示しています。これらの薬剤はプレシジョン・オンコロジーにおける重要な進歩であり、臨床医が患者の特定の遺伝子変化に治療を適合させることを可能にするからです。現在進行中の臨床試験では、現在の治療に対する耐性を克服することを目的とした併用療法、免疫療法、その他の新規薬剤が検討されています。このような進歩にもかかわらず、治療の副作用と最終的な病勢進行のリスクは依然として課題であり、継続的なモニタリングと治療戦略の調整が必要です。さらに、これらの治療法へのアクセスは、ヘルスケアインフラや保険適用範囲によって異なることがあり、地域によって治療成績に影響を与えます。研究により標的治療薬が拡充されるにつれ、進行性MTC患者の見通しは改善されつつあるが、長期的な管理には有効性、安全性、QOLのバランスを慎重に考慮する必要があります。

甲状腺髄様がん市場の成長とイノベーションを促進する主な要因は？

甲状腺髄様がん市場の成長は、診断技術革新、医薬品開発、患者の意識向上、ヘルスケアインフラの拡充に関連するいくつかの力が交差することによってもたらされます。第一に、定期的な頸部超音波検査と細針吸引生検の普及により、甲状腺結節の早期発見が可能になり、その一部はフォローアップの分子生化学的検査によりMTCと同定されます。第二に、MEN 2のような遺伝性症候群に対する医師や一般の人々の認識が高まり、遺伝カウンセリングや高リスク家族の早期スクリーニングに対する需要が高まっています。第三に、ゲノミクスとプレシジョンメディシンの継続的な進歩が、生存予後を改善し、進行した疾患の患者に新たな希望を与える標的治療の開発に拍車をかけています。第四に、製薬企業による希少疾病用医薬品開発への投資が、MTCのような希少がんに対する治療法の研究と商業化を促進し、より強固な治療パイプラインを生み出しています。第5に、デジタルヘルスツールや患者支援プラットフォームの普及により、セカンドオピニオンへのアクセス、臨床試験への参加、より良いケア管理が可能になっています。第6に、新興国におけるヘルスケアへのアクセス拡大により、格差は依然として存在するもの、診断率と治療率が徐々に向上しています。第7に、ファスト・トラック指定や希少疾病用医薬品の承認を通じた規制当局の支援により、新しい治療法の上市までの時間が早まっています。最後に、内分泌学、腫瘍学、遺伝学、外科学を統合した集学的治療モデルが、協調的かつ包括的な治療を通じて患者の転帰を向上させています。これらの市場促進要因は総体として、甲状腺髄様がんに罹患した患者の診断、治療、QOLの改善に焦点を当てた、成長し、ますます洗練された市場を支えています。

セグメント

治療（外科治療、放射線治療、化学療法治療）;最終用途（病院、放射線治療センター、がん研究機関）

調査対象企業の例

  • AstraZeneca PLC
  • Bayer AG
  • BeOne Medicines
  • Blueprint Medicines
  • Crinetics Pharmaceuticals
  • Eli Lilly and Company
  • Epizyme, Inc.
  • Exelixis, Inc.
  • F. Hoffmann-La Roche Ltd
  • GSK（GlaxoSmithKline）
  • Ipsen
  • Janssen（Johnson & Johnson）
  • Jiangsu Hengrui Medicine
  • Loxo Oncology（Eli Lilly subsidiary）
  • Millennium Pharmaceuticals（Takeda）
  • Novo Nordisk
  • Pfizer Inc.
  • Rigel Pharmaceuticals
  • Sanofi AG
  • Takeda Pharmaceutical Company

AIインテグレーション

Global Industry Analystsは、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革しています。

Global Industry Analystsは、一般的なLLMや業界固有のSLMにクエリーする代わりに、ビデオ記録、ブログ、検索エンジン調査、大量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP37362

Global Medullary Thyroid Cancer Market to Reach US$2.2 Billion by 2030

The global market for Medullary Thyroid Cancer estimated at US$1.4 Billion in the year 2024, is expected to reach US$2.2 Billion by 2030, growing at a CAGR of 7.6% over the analysis period 2024-2030. Surgery Treatment, one of the segments analyzed in the report, is expected to record a 8.9% CAGR and reach US$1.4 Billion by the end of the analysis period. Growth in the Radiation Therapy Treatment segment is estimated at 5.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$383.3 Million While China is Forecast to Grow at 12.1% CAGR

The Medullary Thyroid Cancer market in the U.S. is estimated at US$383.3 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$468.0 Million by the year 2030 trailing a CAGR of 12.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.7% and 7.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.0% CAGR.

Global Medullary Thyroid Cancer Market - Key Trends & Drivers Summarized

What Makes Medullary Thyroid Cancer Unique Among Thyroid Malignancies?

Medullary thyroid cancer (MTC) stands out as a distinct and relatively rare form of thyroid malignancy, accounting for approximately 3 to 4 percent of all thyroid cancer cases worldwide. Unlike the more common papillary and follicular thyroid cancers, which originate from follicular cells, MTC arises from parafollicular C cells that produce the hormone calcitonin. This unique origin gives MTC a different biological behavior, clinical presentation, and treatment approach. MTC can occur sporadically or as part of inherited syndromes such as multiple endocrine neoplasia type 2 (MEN 2), making genetic testing a cornerstone of diagnosis and risk stratification. The presence of elevated calcitonin and carcinoembryonic antigen (CEA) levels serves as important biomarkers for early detection and disease monitoring. Unlike differentiated thyroid cancers, MTC does not typically absorb radioactive iodine, limiting the effectiveness of traditional thyroid cancer therapies. Surgical resection remains the primary curative intervention, often involving total thyroidectomy and lymph node dissection. However, the disease’s propensity for early lymphatic spread and distant metastasis, especially to the liver and lungs, complicates long-term management. Additionally, patients with inherited forms often present at a younger age and may develop other endocrine tumors, further increasing clinical complexity. These factors underscore the need for early diagnosis, tailored treatment strategies, and lifelong monitoring, making MTC one of the most challenging thyroid cancers to manage clinically.

How Are Advances in Molecular Biology and Genetic Testing Reshaping Diagnosis and Risk Assessment?

The understanding of medullary thyroid cancer has been significantly enhanced by advances in molecular biology and genetic testing, which have become integral to both diagnosis and risk assessment. The identification of mutations in the RET proto-oncogene has been a landmark development, particularly in cases associated with familial syndromes such as MEN 2A and MEN 2B. Genetic screening of at-risk individuals allows for early detection and prophylactic thyroidectomy, which has been shown to dramatically improve survival outcomes. In sporadic cases, somatic RET mutations and RAS mutations offer insights into tumor behavior and potential therapeutic responses. The ability to stratify patients based on their genetic profiles has led to more personalized treatment approaches and follow-up protocols. Molecular diagnostics also facilitate differentiation between benign and malignant thyroid nodules when traditional imaging and cytology are inconclusive. Liquid biopsy techniques, though still emerging, show promise for non-invasive monitoring of disease progression and recurrence. These molecular insights are complemented by serum biomarkers such as calcitonin and CEA, which serve as reliable indicators of tumor burden and treatment response. Furthermore, genetic counseling has become a critical component of care for patients with hereditary forms of MTC, allowing for family-wide risk assessment and preventive strategies. As precision medicine continues to evolve, the integration of genetic and molecular data is expected to further refine diagnostic accuracy and improve individualized management for patients with this aggressive form of thyroid cancer.

What Role Do Targeted Therapies and Novel Drugs Play in Changing the Treatment Landscape?

The treatment landscape for medullary thyroid cancer has undergone a transformative shift with the advent of targeted therapies and novel drug development. For patients with advanced, inoperable, or metastatic MTC, traditional chemotherapy and radiotherapy offer limited efficacy, prompting a search for more effective systemic treatments. Tyrosine kinase inhibitors (TKIs) such as vandetanib and cabozantinib have emerged as the frontline therapies in such cases, particularly for patients with progressive disease. These agents work by inhibiting RET and other pathways involved in tumor growth and angiogenesis, offering prolonged progression-free survival and disease control. More recently, highly selective RET inhibitors like selpercatinib and pralsetinib have demonstrated significant clinical benefits with fewer off-target effects, especially in patients with RET-mutant tumors. These drugs represent a significant advancement in precision oncology, as they allow clinicians to match treatment with a patient’s specific genetic alterations. Ongoing clinical trials are exploring combination therapies, immunotherapies, and other novel agents aimed at overcoming resistance to current treatments. Despite these advances, treatment side effects and the risk of eventual disease progression remain challenges, necessitating continuous monitoring and adjustment of therapeutic strategies. Additionally, access to these therapies can vary based on healthcare infrastructure and insurance coverage, influencing outcomes in different regions. As research continues to expand the arsenal of targeted treatments, the outlook for patients with advanced MTC is improving, though long-term management still requires a careful balance of efficacy, safety, and quality of life considerations.

What Are the Key Drivers Fueling Growth and Innovation in the Medullary Thyroid Cancer Market?

The growth in the medullary thyroid cancer market is driven by several intersecting forces related to diagnostic innovation, drug development, patient awareness, and healthcare infrastructure expansion. First, increased use of routine neck ultrasounds and fine-needle aspiration biopsies has led to earlier detection of thyroid nodules, some of which are identified as MTC through follow-up molecular and biochemical testing. Second, rising awareness of genetic syndromes like MEN 2 among physicians and the public has led to greater demand for genetic counseling and early screening in high-risk families. Third, ongoing advances in genomics and precision medicine are fueling the development of targeted therapies that improve survival outcomes and offer new hope to patients with advanced disease. Fourth, investment by pharmaceutical companies in orphan drug development is incentivizing research and commercialization of therapies for rare cancers like MTC, resulting in a more robust treatment pipeline. Fifth, the proliferation of digital health tools and patient advocacy platforms is enabling individuals to access second opinions, participate in clinical trials, and better manage their care. Sixth, expanding access to healthcare in emerging economies is gradually improving diagnosis and treatment rates, although disparities still exist. Seventh, regulatory support through fast-track designations and orphan drug approvals is accelerating the time to market for new treatments. Lastly, multidisciplinary care models integrating endocrinology, oncology, genetics, and surgery are enhancing patient outcomes through coordinated and comprehensive care. These drivers collectively support a growing and increasingly sophisticated market focused on improving diagnosis, treatment, and quality of life for patients affected by medullary thyroid cancer.

SCOPE OF STUDY:

The report analyzes the Medullary Thyroid Cancer market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Treatment (Surgery Treatment, Radiation Therapy Treatment, Chemotherapy Treatment); End-Use (Hospitals End-Use, Radiation Therapy Center End-Use, Cancer Research Institutes End-Use)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 44 Featured) -

  • AstraZeneca PLC
  • Bayer AG
  • BeOne Medicines
  • Blueprint Medicines
  • Crinetics Pharmaceuticals
  • Eli Lilly and Company
  • Epizyme, Inc.
  • Exelixis, Inc.
  • F. Hoffmann-La Roche Ltd
  • GSK (GlaxoSmithKline)
  • Ipsen
  • Janssen (Johnson & Johnson)
  • Jiangsu Hengrui Medicine
  • Loxo Oncology (Eli Lilly subsidiary)
  • Millennium Pharmaceuticals (Takeda)
  • Novo Nordisk
  • Pfizer Inc.
  • Rigel Pharmaceuticals
  • Sanofi AG
  • Takeda Pharmaceutical Company

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Medullary Thyroid Cancer - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Awareness and Early Diagnosis Efforts Throw the Spotlight on Medullary Thyroid Cancer Detection Pathways
    • Advances in Genetic Screening Propel Growth in RET Mutation Testing and Targeted Therapy Eligibility
    • Increased Incidence of Sporadic and Hereditary MTC Expands the Addressable Market Opportunity for Targeted Therapeutics
    • Approvals of RET Inhibitors Strengthen the Business Case for Precision Medicine in MTC Management
    • Expansion of Next-Generation Sequencing (NGS) in Oncology Accelerates Demand for Molecular Diagnostic Solutions
    • Unmet Needs in Late-Stage and Metastatic MTC Drive Clinical Interest in Novel Combination Therapies
    • Growing Role of Multidisciplinary Care Models Sustains Demand for Coordinated Treatment Planning Tools
    • Tele-oncology and Remote Monitoring Trends Enhance Access to Specialist Care for MTC Patients in Underserved Regions
    • Pharmaceutical Innovation in Kinase Inhibitors Generates New Hope for Progressive or Refractory MTC Cases
    • Increased Use of Biomarkers like Calcitonin and CEA Drives Growth in Longitudinal Monitoring Solutions
    • Global Expansion of Cancer Genomics Programs Opens New Pathways for MTC Identification and Stratified Treatment
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Medullary Thyroid Cancer Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Medullary Thyroid Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Medullary Thyroid Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Surgery Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Surgery Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Surgery Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Radiation Therapy Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Radiation Therapy Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Radiation Therapy Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Chemotherapy Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Chemotherapy Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Chemotherapy Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Hospitals End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Radiation Therapy Center End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Radiation Therapy Center End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Radiation Therapy Center End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Cancer Research Institutes End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Cancer Research Institutes End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 22: World 16-Year Perspective for Cancer Research Institutes End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Medullary Thyroid Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 23: USA Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 25: USA 16-Year Perspective for Medullary Thyroid Cancer by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment for the Years 2014, 2025 & 2030
    • TABLE 26: USA Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 28: USA 16-Year Perspective for Medullary Thyroid Cancer by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 29: Canada Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 30: Canada Historic Review for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 31: Canada 16-Year Perspective for Medullary Thyroid Cancer by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment for the Years 2014, 2025 & 2030
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Canada Historic Review for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 34: Canada 16-Year Perspective for Medullary Thyroid Cancer by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use for the Years 2014, 2025 & 2030
  • JAPAN
    • Medullary Thyroid Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 35: Japan Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Japan Historic Review for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 37: Japan 16-Year Perspective for Medullary Thyroid Cancer by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment for the Years 2014, 2025 & 2030
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Japan Historic Review for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 40: Japan 16-Year Perspective for Medullary Thyroid Cancer by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use for the Years 2014, 2025 & 2030
  • CHINA
    • Medullary Thyroid Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 41: China Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: China Historic Review for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 43: China 16-Year Perspective for Medullary Thyroid Cancer by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment for the Years 2014, 2025 & 2030
    • TABLE 44: China Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: China Historic Review for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 46: China 16-Year Perspective for Medullary Thyroid Cancer by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use for the Years 2014, 2025 & 2030
  • EUROPE
    • Medullary Thyroid Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Medullary Thyroid Cancer by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 49: Europe 16-Year Perspective for Medullary Thyroid Cancer by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 52: Europe 16-Year Perspective for Medullary Thyroid Cancer by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment for the Years 2014, 2025 & 2030
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 55: Europe 16-Year Perspective for Medullary Thyroid Cancer by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use for the Years 2014, 2025 & 2030
  • FRANCE
    • Medullary Thyroid Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 56: France Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: France Historic Review for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 58: France 16-Year Perspective for Medullary Thyroid Cancer by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment for the Years 2014, 2025 & 2030
    • TABLE 59: France Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: France Historic Review for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 61: France 16-Year Perspective for Medullary Thyroid Cancer by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use for the Years 2014, 2025 & 2030
  • GERMANY
    • Medullary Thyroid Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Germany Historic Review for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 64: Germany 16-Year Perspective for Medullary Thyroid Cancer by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment for the Years 2014, 2025 & 2030
    • TABLE 65: Germany Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Germany Historic Review for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 67: Germany 16-Year Perspective for Medullary Thyroid Cancer by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Italy Historic Review for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 70: Italy 16-Year Perspective for Medullary Thyroid Cancer by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment for the Years 2014, 2025 & 2030
    • TABLE 71: Italy Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Italy Historic Review for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 73: Italy 16-Year Perspective for Medullary Thyroid Cancer by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Medullary Thyroid Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 74: UK Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: UK Historic Review for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 76: UK 16-Year Perspective for Medullary Thyroid Cancer by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment for the Years 2014, 2025 & 2030
    • TABLE 77: UK Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: UK Historic Review for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 79: UK 16-Year Perspective for Medullary Thyroid Cancer by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 80: Spain Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Spain Historic Review for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 82: Spain 16-Year Perspective for Medullary Thyroid Cancer by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment for the Years 2014, 2025 & 2030
    • TABLE 83: Spain Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Spain Historic Review for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 85: Spain 16-Year Perspective for Medullary Thyroid Cancer by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 86: Russia Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Russia Historic Review for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 88: Russia 16-Year Perspective for Medullary Thyroid Cancer by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment for the Years 2014, 2025 & 2030
    • TABLE 89: Russia Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Russia Historic Review for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 91: Russia 16-Year Perspective for Medullary Thyroid Cancer by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Rest of Europe Historic Review for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 94: Rest of Europe 16-Year Perspective for Medullary Thyroid Cancer by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment for the Years 2014, 2025 & 2030
    • TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Rest of Europe Historic Review for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 97: Rest of Europe 16-Year Perspective for Medullary Thyroid Cancer by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Medullary Thyroid Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific Historic Review for Medullary Thyroid Cancer by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 100: Asia-Pacific 16-Year Perspective for Medullary Thyroid Cancer by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 103: Asia-Pacific 16-Year Perspective for Medullary Thyroid Cancer by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment for the Years 2014, 2025 & 2030
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 106: Asia-Pacific 16-Year Perspective for Medullary Thyroid Cancer by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Medullary Thyroid Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 107: Australia Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Australia Historic Review for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 109: Australia 16-Year Perspective for Medullary Thyroid Cancer by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment for the Years 2014, 2025 & 2030
    • TABLE 110: Australia Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Australia Historic Review for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 112: Australia 16-Year Perspective for Medullary Thyroid Cancer by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use for the Years 2014, 2025 & 2030
  • INDIA
    • Medullary Thyroid Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 113: India Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: India Historic Review for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 115: India 16-Year Perspective for Medullary Thyroid Cancer by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment for the Years 2014, 2025 & 2030
    • TABLE 116: India Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: India Historic Review for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 118: India 16-Year Perspective for Medullary Thyroid Cancer by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 119: South Korea Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: South Korea Historic Review for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 121: South Korea 16-Year Perspective for Medullary Thyroid Cancer by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment for the Years 2014, 2025 & 2030
    • TABLE 122: South Korea Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: South Korea Historic Review for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 124: South Korea 16-Year Perspective for Medullary Thyroid Cancer by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 125: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Rest of Asia-Pacific Historic Review for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 127: Rest of Asia-Pacific 16-Year Perspective for Medullary Thyroid Cancer by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment for the Years 2014, 2025 & 2030
    • TABLE 128: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Rest of Asia-Pacific Historic Review for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 130: Rest of Asia-Pacific 16-Year Perspective for Medullary Thyroid Cancer by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Medullary Thyroid Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 131: Latin America Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 132: Latin America Historic Review for Medullary Thyroid Cancer by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 133: Latin America 16-Year Perspective for Medullary Thyroid Cancer by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 136: Latin America 16-Year Perspective for Medullary Thyroid Cancer by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment for the Years 2014, 2025 & 2030
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 139: Latin America 16-Year Perspective for Medullary Thyroid Cancer by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 140: Argentina Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Argentina Historic Review for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 142: Argentina 16-Year Perspective for Medullary Thyroid Cancer by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment for the Years 2014, 2025 & 2030
    • TABLE 143: Argentina Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Argentina Historic Review for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 145: Argentina 16-Year Perspective for Medullary Thyroid Cancer by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 146: Brazil Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Brazil Historic Review for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 148: Brazil 16-Year Perspective for Medullary Thyroid Cancer by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment for the Years 2014, 2025 & 2030
    • TABLE 149: Brazil Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Brazil Historic Review for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 151: Brazil 16-Year Perspective for Medullary Thyroid Cancer by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 152: Mexico Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Mexico Historic Review for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 154: Mexico 16-Year Perspective for Medullary Thyroid Cancer by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment for the Years 2014, 2025 & 2030
    • TABLE 155: Mexico Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Mexico Historic Review for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 157: Mexico 16-Year Perspective for Medullary Thyroid Cancer by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 158: Rest of Latin America Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Rest of Latin America Historic Review for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 160: Rest of Latin America 16-Year Perspective for Medullary Thyroid Cancer by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment for the Years 2014, 2025 & 2030
    • TABLE 161: Rest of Latin America Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Rest of Latin America Historic Review for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 163: Rest of Latin America 16-Year Perspective for Medullary Thyroid Cancer by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Medullary Thyroid Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 164: Middle East Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 165: Middle East Historic Review for Medullary Thyroid Cancer by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 166: Middle East 16-Year Perspective for Medullary Thyroid Cancer by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 169: Middle East 16-Year Perspective for Medullary Thyroid Cancer by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment for the Years 2014, 2025 & 2030
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 172: Middle East 16-Year Perspective for Medullary Thyroid Cancer by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 173: Iran Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Iran Historic Review for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 175: Iran 16-Year Perspective for Medullary Thyroid Cancer by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment for the Years 2014, 2025 & 2030
    • TABLE 176: Iran Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Iran Historic Review for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 178: Iran 16-Year Perspective for Medullary Thyroid Cancer by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 179: Israel Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Israel Historic Review for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 181: Israel 16-Year Perspective for Medullary Thyroid Cancer by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment for the Years 2014, 2025 & 2030
    • TABLE 182: Israel Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Israel Historic Review for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 184: Israel 16-Year Perspective for Medullary Thyroid Cancer by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 185: Saudi Arabia Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Saudi Arabia Historic Review for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 187: Saudi Arabia 16-Year Perspective for Medullary Thyroid Cancer by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment for the Years 2014, 2025 & 2030
    • TABLE 188: Saudi Arabia Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Saudi Arabia Historic Review for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 190: Saudi Arabia 16-Year Perspective for Medullary Thyroid Cancer by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 191: UAE Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 192: UAE Historic Review for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 193: UAE 16-Year Perspective for Medullary Thyroid Cancer by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment for the Years 2014, 2025 & 2030
    • TABLE 194: UAE Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 195: UAE Historic Review for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 196: UAE 16-Year Perspective for Medullary Thyroid Cancer by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 197: Rest of Middle East Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Rest of Middle East Historic Review for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 199: Rest of Middle East 16-Year Perspective for Medullary Thyroid Cancer by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment for the Years 2014, 2025 & 2030
    • TABLE 200: Rest of Middle East Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Rest of Middle East Historic Review for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 202: Rest of Middle East 16-Year Perspective for Medullary Thyroid Cancer by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use for the Years 2014, 2025 & 2030
  • AFRICA
    • Medullary Thyroid Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 203: Africa Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Africa Historic Review for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 205: Africa 16-Year Perspective for Medullary Thyroid Cancer by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment for the Years 2014, 2025 & 2030
    • TABLE 206: Africa Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Africa Historic Review for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 208: Africa 16-Year Perspective for Medullary Thyroid Cancer by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use for the Years 2014, 2025 & 2030

IV. COMPETITION